Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial

Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial

  • April 16, 2026

Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial of its lead asset for sarcoma patients.

Leave A Comment

Fields (*) Mark are Required